Relative search popularity of five advanced prostate cancer medications using Google Trends.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
08 Sep 2023
08 Sep 2023
Historique:
received:
15
03
2023
accepted:
18
08
2023
revised:
27
07
2023
medline:
8
9
2023
pubmed:
8
9
2023
entrez:
7
9
2023
Statut:
aheadofprint
Résumé
There are many FDA-approved drugs for advanced prostate cancer (PC), yet public interest in these drugs is not well understood. We compared public interest and state-level predictors of interest in five common oral adjunctive hormonal therapies. Google Trends™ was queried for: "Enzalutamide", "Abiraterone Acetate", "Bicalutamide", "Apalutamide", and "Darolutamide" in the United States from January 2004 to November 2022. Data are presented as relative search index (RSI) by month. RSI ranges from 0 to 100 with 100 being peak popularity, 50 being half of the peak popularity, and 0 representing insufficient data to be determined. Several drugs abruptly increased in popularity following FDA approval including abiraterone, enzalutamide, and apalutamide. All drugs decreased in popularity from January 2020 to July 2020, corresponding with the COVID-19 pandemic. In the most recent 5 years, enzalutamide and abiraterone were the most common searched drugs, with bicalutamide a close 3 Despite the emergence of more effective medications, bicalutamide remains relatively popular, particularly in states with lower household income, more uninsured adults, or those that did not expand Medicaid, possibly due to its lower cost.
Sections du résumé
BACKGROUND
BACKGROUND
There are many FDA-approved drugs for advanced prostate cancer (PC), yet public interest in these drugs is not well understood. We compared public interest and state-level predictors of interest in five common oral adjunctive hormonal therapies.
METHODS
METHODS
Google Trends™ was queried for: "Enzalutamide", "Abiraterone Acetate", "Bicalutamide", "Apalutamide", and "Darolutamide" in the United States from January 2004 to November 2022. Data are presented as relative search index (RSI) by month. RSI ranges from 0 to 100 with 100 being peak popularity, 50 being half of the peak popularity, and 0 representing insufficient data to be determined.
RESULTS
RESULTS
Several drugs abruptly increased in popularity following FDA approval including abiraterone, enzalutamide, and apalutamide. All drugs decreased in popularity from January 2020 to July 2020, corresponding with the COVID-19 pandemic. In the most recent 5 years, enzalutamide and abiraterone were the most common searched drugs, with bicalutamide a close 3
CONCLUSIONS
CONCLUSIONS
Despite the emergence of more effective medications, bicalutamide remains relatively popular, particularly in states with lower household income, more uninsured adults, or those that did not expand Medicaid, possibly due to its lower cost.
Identifiants
pubmed: 37679603
doi: 10.1038/s41391-023-00716-9
pii: 10.1038/s41391-023-00716-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDDK NIH HHS
ID : TL1 DK132768
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42:354–73. https://doi.org/10.1210/endrev/bnab002 .
doi: 10.1210/endrev/bnab002
pubmed: 33480983
pmcid: 8152444
Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, et al. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int J Clin Oncol. 2020;25:1892–900. https://doi.org/10.1007/s10147-020-01777-9 .
doi: 10.1007/s10147-020-01777-9
pubmed: 32924096
pmcid: 7572325
Vaishampayan UN, Heilbrun LK, Monk P 3rd, Tejwani S, Sonpavde G, Hwang C, et al. Clinical efficacy of enzalutamide vs bicalutamide combined with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a randomized clinical trial. JAMA Netw Open. 2021;4:e2034633. https://doi.org/10.1001/jamanetworkopen.2020.34633 .
doi: 10.1001/jamanetworkopen.2020.34633
pubmed: 33496795
pmcid: 7838941
Koukourakis MI, Kakouratos C, Kalamida D, Mitrakas A, Pouliliou S, Xanthopoulou E, et al. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines. Anticancer Drugs. 2018;29:323–33. https://doi.org/10.1097/cad.0000000000000592 .
doi: 10.1097/cad.0000000000000592
pubmed: 29381490
Ueda T, Shiraishi T, Ito S, Ohashi M, Matsugasumi T, Yamada Y, et al. Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer. Sci Rep. 2021;11:10094. https://doi.org/10.1038/s41598-021-89609-2 .
doi: 10.1038/s41598-021-89609-2
pubmed: 33980956
pmcid: 8115638
Siemens DR, Klotz L, Heidenreich A, Chowdhury S, Villers A, Baron B, et al. Efficacy and safety of enzalutamide vs bicalutamide in younger and older patients with metastatic castration resistant prostate cancer in the TERRAIN trial. J Urol. 2018;199:147–54. https://doi.org/10.1016/j.juro.2017.08.080 .
doi: 10.1016/j.juro.2017.08.080
pubmed: 28827103
Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I. J Urol. 2021;205:14–21. https://doi.org/10.1097/ju.0000000000001375 .
doi: 10.1097/ju.0000000000001375
pubmed: 32960679
Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART II. J Urol. 2021;205:22–9. https://doi.org/10.1097/ju.0000000000001376 .
doi: 10.1097/ju.0000000000001376
pubmed: 32960678
Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32:3436–48. https://doi.org/10.1200/jco.2013.54.8404 .
doi: 10.1200/jco.2013.54.8404
pubmed: 25199761
pmcid: 4876355
KFF. 2022/04/21/T16:15:42+00:00. 2022. https://www.kff.org/statedata/ .
Danila DC, Rathkopf DE, Morris MJ, Slovin SF, Schwartz LH, Farmer K, et al. Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy. J Clin Oncol. 2008;26:5019. https://doi.org/10.1200/jco.2008.26.15_suppl.5019 .
doi: 10.1200/jco.2008.26.15_suppl.5019
FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer. FDA. 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abiraterone-acetate-combination-prednisone-high-risk-metastatic-castration-sensitive .
Drug Approval Package: Xtandi (enzalutamide) NDA # 203415. 2012. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415Orig1s000Approv.pdf .
FDA approves apalutamide for non-metastatic castration-resistant prostate cancer. FDA. 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-apalutamide-non-metastatic-castration-resistant-prostate-cancer .
United States - COVID-19 Overview - Johns Hopkins. Johns Hopkins Coronavirus Resource Center. 2022. https://coronavirus.jhu.edu/map.html .
KFF. 2022/11/09/T14:44:01+00:00. 2022. https://www.kff.org/medicaid/issue-brief/status-of-state-medicaid-expansion-decisions-interactive-map/ .
Chopra A, Georgieva M, Lopes G, Yeo CM, Haaland B. Abiraterone or enzalutamide in advanced castration-resistant prostate cancer: an indirect comparison. Prostate. 2017;77:639–46. https://doi.org/10.1002/pros.23309 .
doi: 10.1002/pros.23309
pubmed: 28101887
Kang M, Jeong CW, Kwak C, Ku JH, Kim HH. Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials. Oncotarget. 2017;8:59690–7. https://doi.org/10.18632/oncotarget.17741 .
doi: 10.18632/oncotarget.17741
pubmed: 28938672
pmcid: 5601768
Carvalho RM, Santos LDN, Ramos PM, Machado CJ, Acioly P, Frattini SC, et al. Bicalutamide and the new perspectives for female pattern hair loss treatment: what dermatologists should know. J Cosmet Dermatol. 2022;21:4171–5. https://doi.org/10.1111/jocd.14773 .
doi: 10.1111/jocd.14773
pubmed: 35032336
Data.Medicaid.gov. State Drug Utilization Data 2021. Accessed August 21, 2023. https://data.medicaid.gov/dataset/eec7fbe6-c4c4-5915-b3d0-be5828ef4e9d .
Ali AM, Cobran EK, Young HN. Barriers associated with access to prescription medications in patients diagnosed with type 2 diabetes mellitus treated at federally qualified health centers. Pharmacy. 2022;10. https://doi.org/10.3390/pharmacy10040079 .
West JC, Wilk JE, Rae DS, Muszynski IS, Stipec MR, Alter CL, et al. Medicaid prescription drug policies and medication access and continuity: findings from ten states. Psychiatr Serv. 2009;60:601–10. https://doi.org/10.1176/ps.2009.60.5.601 .
doi: 10.1176/ps.2009.60.5.601
pubmed: 19411346
Anawalt BD. Chapter 140 - Gynecomastia. In: Jameson JL, De Groot LJ, de Kretser DM, Giudice LC, Grossman AB, Melmed S, et al., editors. Endocrinology: adult and pediatric, 7th ed. Philadelphia: W.B. Saunders; 2016. p. 2421–30.e5.
Randolph JF Jr. Gender-affirming hormone therapy for transgender females. Clin Obstet Gynecol. 2018;61:705–21. https://doi.org/10.1097/grf.0000000000000396 .
doi: 10.1097/grf.0000000000000396
pubmed: 30256230